City Therapeutics, an innovative leader in the realm of RNA interference (RNAi), has successfully raised $135 million in a recent funding round. Founded by a team of pioneering executives and scientists, City Therapeutics is dedicated to advancing the next generation of small interfering RNAs (siRNAs) – critical molecules that act as the "triggers" for RNAi processes. With this substantial influx of capital, the company aims to enhance its research and development efforts, driving forward its mission to become the premier RNAi therapeutics company. The funds will primarily be allocated towards the development of their cutting-edge siRNA technologies, which possess the potential to revolutionize treatment approaches for a wide variety of diseases, ranging from genetic disorders to prevalent illnesses such as cancer and cardiovascular diseases. As the medical landscape continues to evolve, City Therapeutics is focused on unlocking RNAi’s transformative potential to improve patient outcomes and streamline therapeutic processes. With this recent funding, the company is poised to expand its capabilities, potentially offering novel treatment options that can address complex health challenges ahead. By leveraging their advanced scientific expertise and cutting-edge technologies, City Therapeutics is not only advancing the field of RNAi but is also committed to making a significant impact on global health and wellness. This latest infusion of capital marks a key milestone for the company as it accelerates its path towards groundbreaking discoveries in RNAi-based therapies that will benefit patients worldwide.
City Therapeutics Secures $135 Million in Funding to Advance RNAi-Based Medicines
Get the full City Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Maneva
Maneva AI revolutionizes manufacturing by offering a superhuman digital workforce tailored to the industry's unique needs. Our AI empowers factories to streamline operations, cut costs, and enhance productivity. Designed specifically for manufacturing, Maneva AI delivers a range of benefits, from reducing labor dependencies and enhancing quality assurance to eliminating downtime and preserving critical knowledge. Our seamless implementation ensures swift integration into existing workflows, guaranteeing remarkable returns on investment for manufacturers across America. Even tasks once deemed unautomatable are effortlessly handled by Maneva AI. Many challenges facing manufacturing companies, too intricate for costly automation projects, find solutions in our intelligent systems. Leveraging manufacturing-specific intelligence, Maneva AI consistently proves its efficacy, bringing companies closer to a future-proof state. Experience tangible, profitable, and tactical results with Maneva AI. Reach out now to discover how we can drive immediate impact for your business!
$27.0M Series a
today
Avon Health
Avon Health is powering next-gen healthcare. The Avon EMR is an AI-forward, infinitely customizable EMR to power next-gen care delivery practices, from solo primary clinics with 400 patients to virtual care companies with 100,000+ patients. Our customizable modules and APIs have enabled care delivery companies to customize their EMR and patient engagement platform in days, complete with functionality to treat patients in-person and virtually, bill insurance, automatically scribe medical notes using AI, automate workflows, and more.
$9.0M Seed
today
Wassist
The WhatsApp Agents Platform. Engage customers where they already chat. Hyper-personalized conversations with no invasive tracking, where you can checkout in your chat.
$1.1M Seed
today
Cordon Technologies
The world is in the middle of an AI and Robotics revolution. Cordon is bringing this to vineyards, reducing costs and allowing better, more sustainable farming. We are farmers ourselves. Cordon's solutions are reliable, robust, cost effective, and integrate seamlessly with your current machinery and day to day operations.
$1.3M Seed
today
Infinity Constellation
Infinity Constellation is the first AI services holding company, building category leaders designed to displace incumbents in the $9T+ professional services market. We give exceptional operators a 12-month head start—backed by capital, shared infrastructure, customers, back-office support, and shared equity—to launch outcome-driven businesses that redefine their industries.
$24.0M Series a
today